Hoppa till innehållet
Redeye alters the medium-term growth outlook on the back of a very upbeat CMD held by Tobii Dynavox last week. We have long been optimistic about the Tobii Dynvox growth story. The recent CMD displayed management’s firm conviction in the long-term growth possibilities with improving profitability. The new target is ambitious and comes after two solid years. We believe it is possible to reach, especially as M&A is included. We have increased our organic growth expectancy for 2025-2027e with a slight margin increase in 2026e. These changes increase our fair value range and Base case value.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/